36749-01-6

Upstream product

• 621-38-5 3-bromoacetanilide 
• 64-19-7 acetic acid 
• 7693-52-9 4-bromo-2-nitrophenol 
• 106-41-2 4-bromo-phenol 
• 40925-68-6 2-amino-4-bromo-phenol 
• 108-24-7 acetic anhydride 

Downstream Products

• 1053733-51-9 (3aS,4R,8R,8aS)-5,7-Bis-(3-acetyl-benzyl)-2,2-dimethyl-4,8-bis-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethyl)-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one 
• 105655-01-4 6-bromo-3, 4-dihydro-2H-benzo[β][1, 4]oxazine 
• 107986-49-2 N-(5-bromo-2-hydroxyphenyl)acetamide 

Relevant academic research and scientific papers

Palladium-catalyzed C-H activation of anilides at room temperature: Ortho-arylation and acetoxylation

Room-temperature ortho-arylation and acetoxylation of anilides have been achieved using cationic palladium (Pd[TFA]+) as catalyst and (NH 4)2S2O8 as oxidant. Preliminary investigation of the mechanism

BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR

The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.

Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: Synthesis, structure-activity relationship, and X-ray crystal structure analysis

We present several novel P1/P1' substituents that can replace the characteristic benzyl P1/P1' moiety of the cyclic urea based HIV protease inhibitor series. These substituents typically provide 5-10-fold improvements in binding affinity compared to the unsubstituted benzyl analogs. The best substituent was the 3,4-(ethylenedioxy)benzyl group. Proper balancing of the molecule's lipophilicity facilitated the transfer of this improved binding affinity into a superior cellular antiviral activity profile. Several analogs were evaluated further for protein binding and resistance liabilities. Compound 18 (IC90 = 8.7 nM) was chosen for oral bioavailability studies based on its log P and solubility profile. A 10 mg/kg dose in dogs provided modest bioavailability with C(max) = 0.22 μg/mL. X-ray crystallographic analysis of two analogs revealed several interesting features responsible for the 3,4-(ethylenedioxy)benzyl-substituted analog's potency: (1) Comparing the two complexes revealed two distinct binding modes for each P1/P1' substituent; (2) The ethylenedioxy moieties are within 3.6 A? of Pro 81 providing additional van der Waals contacts missing from the parent structure; (3) The enzyme's Arg 8 side chain moves away from the P1 substituent to accommodate the increased steric volume while maintaining a favorable hydrogen bond distance between the para oxygen substituent and the guanidine NH.